AMDKodiak Sciences (KOD) Why AMD fueled the stock 180% HigherKodiak Sciences stock surged over 170 percent following positive Phase 3 trial results for its wet age-related macular degeneration treatments, Zenkuda and KSI-501.Tran ThiSeptember 29, 2026